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Pregnancy-associated serum  
N-glycome changes studied by 
high-throughput MALDI-TOF-MS
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David Falck1, Guinevere S. M. Kammeijer1, Radboud J. E. M. Dolhain2, Yoann Rombouts1,3,4 & 
Manfred Wuhrer1
Pregnancy requires partial suppression of the immune system to ensure maternal-foetal tolerance. 
Protein glycosylation, and especially terminal sialic acid linkages, are of prime importance in regulating 
the pro- and anti-inflammatory immune responses. However, little is known about pregnancy-
associated changes of the serum N-glycome and sialic acid linkages. Using a combination of recently 
developed methods, i.e. derivatisation that allows the distinction between α2,3- and α2,6-linked 
sialic acids by high-throughput MALDI-TOF-MS and software-assisted data processing, we analysed 
the serum N-glycome of a cohort of 29 healthy women at 6 time points during and after pregnancy. A 
total of 77 N-glycans were followed over time, confirming in part previous findings while also revealing 
novel associations (e.g. an increase of FA2BG1S1(6), FA2G1S1(6) and A2BG2S2(6) with delivery). 
From the individual glycans we calculated 42 derived traits. With these, an increase during pregnancy 
and decrease after delivery was observed for both α2,3- and α2,6-linked sialylation. Additionally, a 
difference in the recovery speed after delivery was observed for α2,3- and α2,6-linked sialylation of 
triantennary glycans. In conclusion, our new high-throughput workflow allowed the identification of 
novel plasma glycosylation changes with pregnancy.
Glycosylation is the most common post-translational modification, and is one of the main factors regulating 
innate and adaptive immune responses1. Changes in glycosylation have been associated with various phys-
iological (e.g. age and sex) and pathological conditions (e.g. infection, autoimmune disease and cancer)2–4. 
Disease-associated changes in glycosylation have been reported for various serum proteins, including acute phase 
proteins (e.g. α 1-acid glycoprotein (AGP), hemopexin and haptoglobin (HPT)) and immunoglobulins, produced 
by liver cells and plasma B-cells respectively5,6. In particular, the levels of α 2,6-linked sialylation and galactosyl-
ation of the N-glycan in the immunoglobulin G (IgG) fragment crystallisable (Fc)-domain have been correlated 
with the severity of various diseases including rheumatoid arthritis (RA) and inflammatory bowel disease3,6–9. 
Additionally, sialylation and galactosylation are known to regulate the inflammatory properties of IgG, by modi-
fying its tertiary structure and interaction with receptors such as the Fc-receptors, C1q and DC-SIGN10,11.
Various changes in the glycosylation of serum proteins, including IgG and α 1-antitrypsin (AAT), have been 
observed during pregnancy3,12,13. Pregnancy poses major immunological challenges due to genetic and antigenic 
differences between mother and child14. Partial suppression of the maternal immune system is required to ensure 
tolerance of the foetus, and one may hypothesize that glycosylation plays a role in this15. Pregnancy leads to an 
increase in IgG Fc-linked N-glycan galactosylation and sialylation, two features with a proven anti-inflammatory 
role (regarding sialylation only with α 2,6- and not α 2,3-linked sialic acids)3,16,17.
Protein glycosylation changes studied in individual proteins show highly specific correlations, but such tar-
geted approaches may be blind to biologically important changes originating from other glycoproteins within 
the serum pool. As an example, the analysis of the total serum N-glycome (TSNG) allows the observation of 
sialyl-Lewis antigens (sialyl-Lewis X or sialyl-Lewis A), which are well-known glycan epitopes involved in 
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immunity and inflammation18,19. In contrast, targeted analysis of IgG glycosylation would miss the observation of 
a sialyl-Lewis motif, for the simple reason that none of the IgG glycoforms contain this epitope20.
The profiling of a complex sample, such as TSNG, can be performed using a combination of separation and 
detection methods. For example, HILIC (hydrophilic interaction liquid chromatography) may be combined with 
either CGE-LIF (capillary gel electrophoresis - laser induced fluorescence) or HPLC-FL (high-performance liquid 
chromatography - fluorescence)12,21. Alternatively, glycans can be permethylated and measured by LC-MS (liquid 
chromatography - mass spectrometry)22. A different technique extensively used for high-throughput profiling 
is MALDI-TOF-MS (matrix-assisted laser desorption/ionization - time-of-flight - mass spectrometry), which 
allows for the acquisition of a glycan spectrum within seconds, while LC based methods generally require much 
more time23,24. Moreover, technical challenges posed by the instability and ionization bias observed for sialylated 
glycans have been successfully overcome by permethylation as well as by selective stabilisation of sialic acids by e.g. 
ethyl esterification25–30. The latter method introduces a mass difference between α 2,3- and an α 2,6-linked sialic 
acids, allowing their discrimination by mass spectrometry, and is well suited for high-throughput N-glycan pro-
filing using MALDI-TOF-MS27.
An important issue that arises when analysing larger sample sets by MALDI-TOF-MS is data processing, 
which is often the rate-limiting step. The recently developed processing software package, MassyTools, offers a 
valid solution to this problem by rapidly integrating a predefined list of analytes from any number of mass spec-
tra31. Additionally, MassyTools calculates a wide variety of spectral and analyte quality criteria that allow for an 
efficient and reliable automated curation of (clinical) data.
In this study, we applied high-throughput MALDI-TOF-MS profiling together with a newly developed, auto-
mated data processing tool to the TSNG analysis of a longitudinal cohort of healthy women (n = 29) encom-
passing time points during pregnancy and after delivery31. Pregnancy-associated glycosylation changes have 
previously been studied in this cohort for specific proteins such as IgG, AAT and immunoglobulin A (IgA), as well 
as for serum glycans using CGE-LIF methodology12,32. The use of derived traits allowed us to obtain additional 
biological insight, as the calculated derived traits are mainly based on single enzymatic step monosaccharide 
modifications. Furthermore, the method allowed us to identify more glycans with a higher confidence, including 
differentiation of some isomers, than with the previously mentioned CGE-LIF based study. The utilised methods 
for sample preparation, as well as data processing, proved to be fast and reliable. Data analysis revealed previously 
unnoticed N-glycomic changes with differential dynamics in sialylation and abundance of triantennary glycans.
Results
The TSNG profiles of 29 healthy Caucasian women, screened at three time points during pregnancy and 
three time points after delivery, were analysed using MALDI-TOF-MS after enzymatic glycan release and 
linkage-specific sialic acid derivatisation (Fig. 1; Supplementary Fig. S1)27. The entire workflow is displayed in 
Fig. 2. A table showing all integration and curation results is included in the Supplementary Table S1. A set 
of 77 N-glycan compositions were consistently detected and thus quantified in the glycan profiles acquired by 
MALDI-TOF-MS (Supplementary Table S2), from which 42 derived traits were calculated based on the compo-
sitional features (Supplementary Table S3). The retained compositions included 56 sialylated structures, of which 
31 contained α 2,3-linked and 45 contained α 2,6-linked sialylation. Furthermore, we extracted 5 oligomanno-
sidic, 7 hybrid, 32 fucosylated and 13 bisected compositions. All calculated glycosylation traits were compared 
pairwise using a Wilcoxon signed-rank test to highlight differences between time points (Table 1; Supplementary 
Table S4). Additionally, all (77) individual glycan traits were compared pairwise using a Wilcoxon signed-rank 
test (Supplementary Table S5). A summary of the individual glycan results can be found in the Supplementary 
Table S6. Bonferroni correction was used to address the multiple testing problem, by adjusting the significance 
threshold (e.g. a significance level α < 0.0012 for 42 tests per time point)33.
Figure 1. Mass spectrometric serum N-glycome profile. Average reflectron positive-ion mode MALDI-
TOF-MS spectrum of ethyl esterified released serum glycans, derived from the 3rd trimester samples of the 29 
participants. Calibrants are underlined. The shown N-glycan structures are based on literature and the observed 
mass27. A more detailed and annotated spectrum is provided as Supplementary Fig. S1.
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TSNG changes during pregnancy. When comparing TSNG glycosylation features between the 1st and 3rd 
trimester (trim) of pregnancy, statistical analyses revealed a rise in the level of triantennary glycans (A3; 10.5% 
to 12.6%; p  =  0.0005; Fig. 3B) as well as complex changes in sialylation patterns: we observed increased levels 
of α 2,3-linked sialylation of complex glycans (AL; 9.4% to 10.8%; p = 0.0003; Fig. 3K), especially in diantennary 
glycans (A2L; 6.2% to 7.1%; p = 0.0004; Fig. 3L). Furthermore, there was an increase of α 2,6-linked sialylation in 
triantennary fucosylated glycans (A3FE; 54.4% to 56.5%; p = 0.0001; Fig. 3T). The increase of sialylation in dian-
tennary glycans is in line with an increase of galactosylation of diantennary fucosylated glycans (A2FG; 86.8% to 
90.1%; p < 0.0001; Fig. 3E). However, we observed only a trend towards an increase in the related traits of galacto-
sylation of all complex type glycans (AG; 96.0% to 97.0%; p = 0.0019; Fig. 3C) and galactosylation of diantennary 
glycans (A2G; 95.8% to 96.9%; p = 0.0014; Fig. 3D). Interestingly, we also observed a trend towards an increase in 
antenna fucosylation, indicative of the presence of a sialyl-Lewis epitope, although this was found non-significant 
after multiple testing correction (0.07% to 0.09%; p = 0.0019; data not shown).
TSNG changes during the short term recovery. During short term recovery after delivery (com-
parison between 3rd trim and 6 weeks postpartum (WPP)) glycosylation changes appeared more pronounced 
than during either pregnancy or long term recovery. Galactosylation levels were overall decreased (AG; 97.0% 
to 95.5%; p = 0.0001; Fig. 3C), a finding directly related to decreased levels of galactosylation of diantennary 
glycans (A2G; 96.9% to 95.1%; p < 0.0001; Fig. 3D) and in particular decreased levels of galactosylation of diant-
ennary fucosylated glycans (A2FG; 90.1% to 85.6%; p < 0.0001; Fig. 3E). Additionally, we found decreased levels 
of α 2,3-linked sialylation: a decrease of α 2,3-linked sialylation of complex glycans was observed (AL; 10.8% to 
9.4%; p = 0.0001; Fig. 3K), in particular for α 2,3-linked sialylation of diantennary glycans (A2L; 7.1% to 6.0%; 
p < 0.0001; Fig. 3L), both fucosylated (A2FL; 11.2% to 9.6%; p = 0.0001; Fig. 3M) and non-fucosylated (A2F0L; 
6.1% to 4.9%; p = 0.0001; Fig. 3N). Additionally, the observed decrease in α 2,3-linked sialylation of triantennary 
glycans (A3L; 31.4% to 28.8%; p = 0.0001; Fig. 3O) can be attributed to a decrease in α 2,3-linked sialylation 
of triantennary non-fucosylated glycans (A3F0L; 30.6% to 27.5%; p < 0.0001; Fig. 3P). Besides a decrease in 
α 2,3-linked sialylation, we also observed a decrease in α 2,6-linked sialylation of complex glycans (AE; 77.2% 
to 75.4%; p = 0.0007; Fig. 3Q). This can be traced to the diantennary glycans (A2E; 80.0% to 77.7%; p = 0.0004; 
Fig. 3R) and further to diantennary fucosylated glycans (A2FE; 48.9% to 46.3%; p = 0.0010; Fig. 3S).
Beyond decreasing levels of galactosylation and sialylation, we also observed increases in bisection and fuco-
sylation. Increased levels of fucosylation (F; 21.9% to 25.5%; p < 0.0001; Fig. 3F) were partly due to an increase 
in fucosylation of diantennary glycans (A2F; 23.3% to 27.4%; p < 0.0001; Fig. 3G). Increased levels of bisection 
(B; 6.5% to 8.6%, p < 0.0001; Fig. 3H) could be further assigned to bisection of diantennary glycans (A2B; 8.0% to 
10.5%; p < 0.0001; Fig. 3I) and to diantennary fucosylated glycans (28.5% to 32.9%; p < 0.0001; Fig. 3J).
Figure 2. Glycomics workflow. The workflows illustrates the sample collection scheme, as well as the steps of 
the glycomics workflow: N-glycans were enzymatically released from serum, ethyl esterified and finally purified 
by HILIC-SPE27. Samples were then measured by MALDI-TOF-MS. Lastly, the resulting profiles were processed 
with MassyTools and SPSS31.
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TSNG changes during the long term recovery. Long term recovery (comparison between 3rd trim 
and 26+ WPP samples) showed changes in the types of glycans, as demonstrated by a decrease of triantennary 
glycans (A3; 12.6% to 9.4%; p = 0.0001; Fig. 3B) and an increase of diantennary glycans (A2; 81.6% to 85.0%; 
p = 0.0004; Fig. 3A). Decreased levels of galactosylation were observed for all glycans (AG; 97.0% to 95.4%; 
p = 0.0001; Fig. 3C), and in particular for diantennary glycans (A2G; 96.9% to 95.2%; p = 0.0001; Fig. 3D), espe-
cially fucosylated (A2FG; 90.1% to 84.9%; p < 0.0001; Fig. 3E). We also identified decreased levels of α 2,3-linked 
sialylation of complex glycans (AL; 10.8% to 8.7%; p = 0.0001; Fig. 3K), especially in diantennary glycans (A2L; 
7.1% to 6.0%; p = 0.0002; Fig. 3L) and diantennary non-fucosylated glycans (A2F0L; 6.1% to 4.8%; p = 0.0003; 
Fig. 3N). Triantennary structures also showed a decrease in levels of α 2,3-linked sialylation (A3L; 31.4% to 29.2%; 
p = 0.0011; Fig. 3O), especially in non-fucosylated structures (A3F0L; 30.6% to 27.9%; p = 0.0010; Fig. 3P). 
Interestingly, the levels of α 2,6-linked sialylation of complex glycans were not changed (77.2% in both 3rd trim 
and 26+ WPP samples). However, the levels of α 2,6-linked sialylation of diantennary fucosylated glycans (A2FE; 
48.9% to 46.2%; p = 0.0008; Fig. 3S) and triantennary fucosylated glycans (A3FE; 56.5% to 55.0%; p = 0.0004; 
Fig. 3T) were decreased. Additionally, we also observed a non-significant decrease in antenna fucosylation (0.09% 
to 0.07%; p = 0.0033; data not shown), indicative of the reduction of a sialyl-Lewis epitope.
Discussion
The total serum N-glycome of a set of 174 serum samples from 29 individuals taken at 3 time points during preg-
nancy and 3 time points after delivery was analysed using a recently developed glycan derivatisation technique 
able to differentiate between α 2,3- and α 2,6-linked N-acetylneuraminic acids (sialic acids)27. This was used in 
combination with high-throughput MALDI-TOF-MS detection and a high-throughput data extraction software 
package31. The sample set has previously been studied by CGE-LIF, showing an increase in highly sialylated di-, 
tri- and tetraantennary glycans and a decrease in diantennary structures with zero or one sialic acid, which was 
confirmed in the current study12. While CGE-LIF potentially differentiates more isomers than the method applied 
herein, the usefulness of the separation is often compromised by the overlap of glycan species due to a necessary 
compromise between resolution and throughput34. MALDI-TOF-MS normally cannot separate isomers without 
fragmentation. However, by combining it with a recently developed sialic acid derivatisation method, we did 
obtain information on the sialic acid linkage27. Furthermore, we applied statistics to the derived glycosylation 
traits instead of individual glycans, as derived traits offer a higher robustness and more directly provide insights 
into changes in glycosylation pathways35. The CGE-LIF study could not use derived traits as the potential overlap 
of glycan species with diverging properties compromises the construction of derived traits with unambiguous 
Trait description
Trait 
name
1st trim. (A) 3rd trim. (B) 6 WPP (C) 26+ WPP (D)
abundance SEM p-value abundance SEM
p-value 
(A-B) abundance SEM
p-value 
(B-C) abundance SEM
p-value 
(B-D)
Triantennary glycans A3 10.5% 0.4% – 12.6% 0.4% 0.0005 12.0% 0.4% 0.2218 9.4% 0.4% 0.0001
Galactosylation of diantennary fucosylated glycans A2FG 86.8% 0.9% – 90.1% 0.6% 0.0000 85.6% 0.7% 0.0000 84.9% 0.7% 0.0000
α 2,3-linked sialylation of complex glycans AL 9.4% 0.2% – 10.8% 0.2% 0.0003 9.4% 0.2% 0.0001 8.7% 0.2% 0.0001
α 2,3-linked sialylation of diantennary glycans A2L 6.2% 0.2% – 7.1% 0.2% 0.0004 6.0% 0.1% 0.0000 6.0% 0.2% 0.0002
α 2,6-linked sialylation of triantennary fucosylated glycans A3FE 54.4% 0.5% – 56.5% 0.5% 0.0001 55.9% 0.4% 0.3044 55.0% 0.5% 0.0004
Galactosylation of all glycans AG 96.0% 0.4% – 97.0% 0.2% 0.0019 95.5% 0.2% 0.0001 95.4% 0.3% 0.0001
Galactosylation of diantennary glycans A2G 95.8% 0.4% – 96.9% 0.2% 0.0014 95.1% 0.3% 0.0000 95.2% 0.3% 0.0001
α 2,3-linked sialylation of diantennary fucosylated glycans A2FL 10.1% 0.4% – 11.2% 0.5% 0.0389 9.6% 0.4% 0.0001 10.4% 0.5% 0.2744
α 2,3-linked sialylation of diantennary non-fucosylated glycans A2F0L 5.2% 0.2% – 6.1% 0.2% 0.0029 4.9% 0.1% 0.0001 4.8% 0.2% 0.0003
α 2,3-linked sialylation of triantennary glycans A3L 30.6% 0.3% – 31.4% 0.4% 0.0213 28.8% 0.3% 0.0001 29.2% 0.4% 0.0011
α 2,3-linked sialylation of triantennary non-fucosylated glycans A3F0L 29.8% 0.4% – 30.6% 0.5% 0.0298 27.5% 0.4% 0.0000 27.9% 0.5% 0.0010
α 2,6-linked sialylation of complex glycans AE 77.3% 0.8% – 77.2% 0.5% 0.9914 75.4% 0.5% 0.0007 77.2% 0.7% 0.8554
α 2,6-linked sialylation of diantennary glycans A2E 79.7% 0.9% – 80.0% 0.7% 0.7213 77.7% 0.6% 0.0004 79.3% 0.8% 0.3164
α 2,6-linked sialylation of diantennary fucosylated glycans A2FE 46.4% 1.0% – 48.9% 0.7% 0.0141 46.3% 0.8% 0.0010 46.2% 0.9% 0.0008
Fucosylation of all glycans F 22.3% 1.0% – 21.9% 0.7% 0.7539 25.5% 0.7% 0.0000 24.5% 1.0% 0.0588
Fucosylation of diantennary glycans A2F 23.8% 1.1% – 23.3% 0.9% 0.7213 27.4% 0.8% 0.0000 25.8% 1.1% 0.1215
Bisection of all glycans B 6.7% 0.5% – 6.5% 0.5% 0.5235 8.6% 0.5% 0.0000 8.1% 0.5% 0.0190
Bisection of diantennary glycans A2B 8.0% 0.6% – 8.0% 0.5% 0.8712 10.5% 0.5% 0.0000 9.5% 0.6% 0.0256
Bisection of diantennary fucosylated glycans A2FB 27.1% 1.3% – 28.5% 1.5% 0.5377 32.9% 1.3% 0.0000 31.6% 1.4% 0.0404
Diantennary glycans A2 83.3% 0.8% – 81.6% 0.4% 0.0071 81.9% 0.6% 0.1567 85.0% 0.6% 0.0004
Table 1.  Pregnancy related changes in glycosylation. The table displays the significant changes of derived 
glycan traits throughout pregnancy. The shown abundance values are the mean followed by the standard error 
of the mean. Comparisons were performed as follows: 1st trimester (trim) vs. 3rd trim, 3rd trim vs. 6 weeks post 
pregnancy (WPP), and 3rd trim vs. 26 WPP. A Wilcoxon signed-rank test was used to compare glycan traits, 
and significant changes are indicated with bold text (significance level α < 0.0012 after Bonferroni correction 
for 42 tests per time point). The direction of each change is marked with an arrow (up for an increase, down for 
a decrease). The formula for trait calculation are given in Supplementary Table S2. Lastly, the values listed for 
galactosylation and sialylation are per antenna.
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Figure 3. Pregnancy-associated serum N-glycosylation changes. The graphs represent the relative 
abundances of significantly changing glycosylation traits: (A) diantennary glycans, (B) triantennary glycans, 
(C) galactosylation of all glycans, (D) galactosylation of diantennary glycans, (E) galactosylation of diantennary 
fucosylated glycans, (F) fucosylation of all glycans, (G) fucosylation of diantennary glycans, (H) bisection of all 
glycans, (I) bisection of diantennary glycans, (J) bisection of diantennary fucosylated glycans, (K) α 2,3-linked 
sialylation of complex glycans, (L) α 2,3-linked sialylation of diantennary glycans, (M) α 2,3-linked sialylation  
of diantennary fucosylated glycans, (N) α 2,3-linked sialylation of diantennary non-fucosylated glycans,  
(O) α 2,3-linked sialylation of triantennary glycans, (P) α 2,3-linked sialylation of triantennary non-fucosylated 
glycans, (Q) α 2,6-linked sialylation of complex glycans, (R) α 2,6-linked sialylation of diantennary glycans, 
(S) α 2,6-linked sialylation of diantennary fucosylated glycans, and (T) α 2,6-linked sialylation of triantennary 
fucosylated glycans. The minimum glycoform structure is displayed in each panel with a red circle indicating 
the feature of interest. The values listed for galactosylation and sialylation are per antenna. The graph shows 
the standard error for each time point. Additionally, significant differences between time points are marked 
with a dashed line and an asterisk. Formulae used for glycosylation trait calculation are given in Supplementary 
Table S2.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:23296 | DOI: 10.1038/srep23296
biological meaning. We compared our results with the CGE-LIF study at the individual glycan level. The com-
parison shows that we reproduced many of the previously measured CGE-LIF results and additionally found 
many novel findings, including glycosylation changes during pregnancy (1st trimester vs. 3rd trimester), and that 
various additional glycoforms, including isomers, change with delivery (3rd trimester vs. 6 WPP) and long term 
recovery (3rd trimester vs. 26+ WPP; Supplementary Table S7). For instance, we observed an increase of H5N5E2, 
H4N5F1E1 and H4N4F1E1 with delivery, while all of these glycans were not detected using CGE. However, 
there were also results that we were not able to reproduce, such as an increase in H5N4 with the delivery. In the 
previous paper the responsible CGE-LIF peak had been assigned to two potential glycoforms, namely H5N4 and 
H4N5F1. In the current study by MALDI-TOF-MS, however, we did not identify the H5N4, while the H4N5F1 
peak we did detect matched the CGE-LIF data. Therefore, in the light of the mass spectrometric data, one possi-
bility would be that the previously detected CGE-LIF peak did not consist of both H5N4 and H4N5F1, but rather 
of only H4N5F1.
The applied MALDI-TOF-MS method showed no changes in either oligomannosidic or hybrid glycans, con-
firming previous results by CGE-LIF12. However, a variety of glycosylation changes was observed in complex 
glycans over time (Fig. 3). The glycosylation changes in serum are caused in part by changes in protein-specific 
glycosylation and in part by changes in glycoprotein levels due to pregnancy (e.g. decreasing levels of AAT and 
IgG)3,12,13,32,36.
We observed an increase in galactosylation of diantennary fucosylated glycans during pregnancy, followed by 
a sharp decrease with delivery (A2FG; Fig. 4). In addition, we observed a trend for increasing α 2,6-linked sialyl-
ation of diantennary fucosylated glycans (A2FE; 46.4% to 48.9%), but this was not significant after multiple test-
ing correction (p = 0.0141). IgG is one of the most prominent serum proteins carrying diantennary fucosylated 
glycans, of which only a small fraction contains α 2,6-linked sialic acids6. The levels of IgG decrease with preg-
nancy from 9.5 mg/mL (7–17 weeks of pregnancy) to 7.8 mg/mL (34–38 weeks), resulting in an increase in the 
contribution of other proteins, such as IgM, to the A2FE trait36. Together with the known increase in α 2,6-linked 
sialylation of IgG N-glycans during pregnancy this results in a major contribution of IgG-related changes to the 
observed increase in A2FE3,32. The fact that this increase is hardly visible in TSNG analysis may indicate that 
changes in other glycoproteins, with respect to concentration and glycosylation, counteract the IgG-associated 
changes. Interestingly, IgM shows an opposite trend with pregnancy with its levels increasing from 1.2 mg/mL 
during 7–17 weeks of pregnancy to 1.46 mg/mL during 34–38 weeks of pregnancy36. While IgM is known to carry 
diantennary core-fucosylated N-glycans with rather high levels of α 2,6-linked sialylation, its glycoform-related 
pregnancy-associated glycosylation changes are not known6,37. Hence, changes in IgM glycosylation over the 
course of pregnancy should be investigated.
Our results show specific longitudinal glycosylation changes in serum triantennary glycans. The levels of 
triantennary structures and their α 2,3- or α 2,6-linked sialylated variants show an increase during pregnancy 
Figure 4. Overview on serum glycosylation changes during pregnancy, with delivery and recovery. 
Glycosylation traits that significantly change throughout pregnancy are shown in a Venn diagram. Traits 
are clustered based on when they showed a change, i.e. pregnancy (1st trimester versus 3rd trimester), short 
term recovery (3rd trimester versus 6 WPP) and the long term recovery (3rd trimester versus 26+ WPP). 
The direction of the change is marked by arrows: an upwards arrow indicates that a trait is increased while a 
downwards arrow indicates that a trait is decreased. The minimum glycoforms structure is displayed next to 
each trait with a red circle indicating the feature of interest for the respective trait. A similar figure for all the 
glycoforms is included as Supplementary Fig. S3.
www.nature.com/scientificreports/
7Scientific RepoRts | 6:23296 | DOI: 10.1038/srep23296
(1st trimester to 3rd trimester) followed by a decrease after delivery (3rd trimester to 6 WPP). This could reflect 
changes in the protein concentrations or glycosylation of abundant glycoproteins that contain triantennary gly-
cans, such as AAT, HPT and AGP6,38–40. The protein concentration of AGP remains stable throughout preg-
nancy, but whether the glycosylation levels change with pregnancy is unknown36. In contrast, AAT and HPT 
both increase in concentration during pregnancy and could therefore be responsible for the observed increase in 
triantennary glycans36. The main function of AAT is to protect tissue from enzymatic attacks41. One may specu-
late that an increase in AAT could be attributed to a mechanism where the developing embryo and its support-
ing structures (placenta and endometrium) are protected from enzymatic attacks by the immune system of the 
mother. Interestingly, the previously mentioned CGE-LIF study on the same cohort also showed increased levels 
of triantennary glycans on AAT during pregnancy12. Therefore, it is likely that a combination of the increasing 
concentration of AAT and the increase in triantennary glycans of AAT make a major contribution to the observed 
increase in triantennary glycans in the TSNG.
The linkage of the sialic acid is of major importance to determine if a sialyl-Lewis epitope is present on a 
glycan. A sialyl-Lewis X or sialyl-Lewis A epitope requires the presence of both a fucose (α 1,3-linked for 
sialyl-Lewis X or α 1,4-linked for sialyl-Lewis A) and an α 2,3-linked sialic acid42. In diantennary glycans the 
fucose is mostly present in the core, while in tri- and tetraantennary glycans it is generally on the antenna, result-
ing in a sialyl-Lewis X or A epitope6. However, we did not observe any changes in relation to the percentage 
of sialyl-Lewis epitopes during and after pregnancy. Our results do show changes in α 2,6-linked sialylation of 
fucosylated triantennary glycans (A3FE; Fig. 3T). In addition, we found changes in α 2,3-linked sialylation of 
triantennary glycans (A3L; Fig. 3O), but this could be further narrowed down to changes in α 2,3-linked sialyla-
tion of non-fucosylated triantennary glycans (A3F0L; Fig. 3P). Therefore, it is apparent that there are no changes 
related to sialyl-Lewis epitopes, or that the changes are obscured by changing glycoprotein levels, such as AAT36.
Many physiological processes are involved in the postpartum recovery of the mother. Homeostasis needs some 
time to re-establish and this is reflected by the changes in the serum glycome. Some traits rapidly change (between 
the 3rd trimester and 6 WPP) and then stabilise (similar levels at 6 and 26+ WPP), while variations in others 
emerge only later in time (significant at 26+ WPP; Fig. 4). For IgG it has been shown for RA patients that the 
glycosylation restores postpartum within the first 6 WPP to a similar level as before the pregnancy3. Accordingly, 
we observed in the current study a similar time course for the galactosylation of diantennary fucosylated glycans. 
Similarly, also α 2,3-linked sialylation of both di- and triantennary glycans, clearly non-IgG related, are examples 
of fast responses32. However, other traits did not recover within the first 6 WPP but only changed after 26 weeks 
or more, namely the number of antennae on complex type glycans and α 2,6-linked sialylation of triantennary 
fucosylated glycans (Fig. 4).
A major advantage of our study design is that patient samples are collected from a longitudinal cohort, 
thereby reducing the impact of biological variance. Consequently, our results can be attributed purely to the 
pregnancy-associated changes. However, a minor drawback is represented by isomeric glycan structures that 
we were unable to resolve. Typical examples include H6N5E2, which could be either a triantennary glycan or 
a diantennary glycan with a LacNAc repeat, and H5N5, which could be either a truncated triantennary glycan 
or a bisected diantennary glycan. Consequently, the use of compositional information to assign a derived trait 
may to a certain extent lead to glycan misclassifications. Therefore, the derived traits are calculated based on the 
most common structure assigned to a distinct composition6. In addition, many glycomic studies deal with age, 
sex and medication as major confounders, but none of these are applicable here as the study encompassed only 
healthy women of roughly the same age (32.1 years, SD ± 4.4 years)4. However, we did not take into account other 
confounders such as breastfeeding, as the resulting group sizes would lead to low statistical power. Despite the 
limitations of our study, the results should be indicative of changes that occur during and after pregnancy, as they 
agree with previous literature12,32.
In conclusion, we observed changes in galactosylation, sialylation and antennarity of the TSNG during preg-
nancy. Furthermore, differences were observed in the galactosylation, bisection, fucosylation, sialylation and 
antennarity of the TSNG after delivery. Lastly, a difference in the recovery speed was observed between α 2,3- and 
α 2,6-linked sialylation of triantennary glycans. However, the biological relevance of the observed changes in the 
sialylation of triantennary structures and their linkages is at present unknown and will require further study.
Methods
Materials. Sodium dodecyl sulphate (SDS), ethanol and trifluoroacetic acid were purchased from Merck 
(Darmstadt, Germany). Nonidet P-40 substitute (NP-40), super-DHB (9:1 mixture of 2,5-dihydroxybenzoic 
acid and 2-hydroxy-5-methoxybenzoic acid)43, sodium hydroxide (NaOH) and 1-hydroxybenzotriazole hydrate 
(HOBt) were acquired from Sigma-Aldrich (Steinheim, Germany). 1-Ethyl-3-(3-(dimethylamino)propyl)carbod-
iimide hydrochloride (EDC) was acquired from Fluorochem (Hadfield United Kingdom). Peptide-N-glycosidase 
F (PNGase F) was supplied by Roche Diagnostics (Mannheim, Germany). Cotton thread was bought from Pipoos 
(Utrecht, The Netherlands). HPLC SupraGradient acetonitrile (ACN) was acquired from Biosolve (Valkenswaard, 
The Netherlands). Peptide calibration standard and an AnchorChip MALDI target plate were purchased from 
Bruker Daltonics (Bremen, Germany). Pooled plasma from 20 healthy human donors was purchased from 
Affinity Biologicals (Ancaster, Canada) and used as control sample. Lastly, water was purified with a Purelab 
Ultra from Elga LabWater (Ede, The Netherlands).
Samples. The sera of 29 healthy Caucasian women (mean age 32.1 years, SD ± 4.4) were obtained at three time 
points during pregnancy (1st, 2nd and 3rd trimester), and three time points after delivery (6, 12 and 26+ WPP). 
Sera were collected within the framework of the nationwide (The Netherlands) prospective Pregnancy-associated 
Amelioration of Rheumatoid Arthritis (PARA) study, designed to investigate the improvement of RA during 
pregnancy44. The study was in compliance with the Helsinki Declaration, informed consent was obtained from 
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all subjects, and the study was approved by the Erasmus University Medical Center Ethics Review Board. A 
total of 174 PARA (6 * 29) serum samples from the healthy control group of the PARA cohort were analysed. 
Furthermore, 10 replicates of a commercially available pooled plasma sample of healthy volunteers were used as a 
technical control, yielding an RSD of the main peak (H5N4E2) of 7% (Supplementary Fig. S4). The use of derived 
traits reduced the technical variation, for instance the RSD of the derived trait ‘galactosylation of all glycans’ (AG) 
was found to be 0.8% for the technical control.
Sample preparation. In order to analyse the TSNG of healthy women during pregnancy, 10 μL serum 
was mixed with 20 μL 2% SDS, prior to denaturation by 10 min incubation at 60 °C. N-glycans were released 
by addition of 20 μL release mixture (1:1 4% NP-40: 5x PBS) containing 1 U PNGase F, followed by overnight 
incubation at 37 °C. Of the 50 μL released glycans, 1 μL was derivatised by ethyl esterification as reported in liter-
ature27. Briefly, the 1 μL sample was added to 20 μL 250 mM EDC + 250 mM HOBt in pure ethanol and incubated 
for 1 h at 37 °C. Following derivatisation, the glycans were purified by hydrophilic interaction liquid chroma-
tography (HILIC)-solid phase extraction (SPE) using cotton thread tips, as described previously32. The cotton 
material, packed into pipette tips, was pre-conditioned by pipetting three times 20 μL water, followed by equili-
bration with three times 20 μL 85% ACN. The samples were mixed with 20 μL ACN and then pipetted through 
the pre-equilibrated cotton material extensively. The tips were sequentially washed three times with 20 μL 85% 
ACN + 1% trifluoroacetic acid and three times with 85% ACN. Glycans were eluted in 10 μL water. Afterwards, 
1 μL of the TSNG SPE eluate was applied to an AnchorChip MALDI target plate, mixed with 1 μL of 5 mg/mL 
super-DHB in 50% aqueous ACN containing 1 mM NaOH, and dried at room temperature.
Data acquisition. Derivatised glycan samples were measured using the reflectron positive ion mode of an 
Ultraflextreme MALDI-TOF-MS (Bruker Daltonics), equipped with a Smartbeam-II laser, and operated by flex-
Control 3.4 build 135. Prior to the measurement, external calibration was performed using a peptide calibration 
standard. Ions were accelerated at 25 kV with 140 ns delayed extraction. Per sum spectrum, a total of 20,000 shots 
were accumulated between m/z 1,000 and m/z 5,000.
MassyTools data processing. Using the flexAnalysis Batch Process program (3.3, build 65), the obtained 
spectra were exported into a text-based format ((x,y) file) consisting of an m/z value coupled with an intensity 
value per line, separated by a tab. In order to perform processing by MassyTools; software freely available at 
https://github.com/Tarskin/MassyTools), we applied the ‘free’ reducing end mass modifier and ‘sodium’ charge 
carrier as general parameters31. Additionally, a single letter code was utilized by the program to refer to mono-
saccharides: H for hexose, N for N-acetylhexosamine, F for fucose, E for an α 2,6-linked N-acetylneuraminic acid 
and L for an α 2,3-linked N-acetylneuraminic acid.
Internal calibration was performed using a minimum of 5 out of a list of 7 potential calibrants passing a 
signal-to-noise (S/N) ratio threshold of 9. Potential calibrants were H5N4E1 (1,982.708 Da), H5N4F1E1 
(2,128.766 Da), H5N4E2 (2,301.835 Da), H6N5E2L1 (2,940.052 Da), H6N5F1E2L1 (3086.110 Da), H7N6E1L3 
(3,532.227 Da) and H7N6E2L2 (3,578.269 Da; [M + Na]+ throughout). Additionally, we required a minimum of 4 
calibrants between m/z 1,000 and m/z 2,333 as well as a minimum of 1 calibrant between m/z 2,333 and m/z 3,667. 
The program was allowed to detect calibrants within a window of m/z 0.4 around the exact mass. The calibra-
tion was assessed by evaluating the mass error of the major calibrant glycan (H5N4E2) and major non-calibrant 
glycan (H5N4E1L1) for the technical control samples. H5N4E2 showed an average mass error of − 0.3 ppm, 
SD ± 1.9 ppm while H5N4E1L1 showed an average mass error of − 3.1 ppm, SD ± 3.0 ppm.
Extraction was performed using a ± m/z 0.49 window. A list of 109 analytes was used for initial extraction 
(Supplementary Table S1). The software was allowed to use an m/z region of 15 around the analyte to identify 
the background area and noise values. Subsequently, spectral and analyte curation was performed. Firstly, the 
“fraction of spectrum in analytes” and “fraction of analyte area above S/N cut-off ” parameters were used for 
spectral curation. The spectral quality criteria of all spectra were found to be within three times SD of the average, 
therefore all spectra were kept for further analysis. Secondly, a quality control (QC) parameter and a S/N cut-off 
were used to curate the analyte list: analytes with an average QC value above 1.8 × 10−4 or an average S/N of 
below 6 were discarded, while analytes with an average QC value below 1.8 × 10−4 and an average S/N of above 
6 (Supplementary Fig. S2) were retained. A total of 77 analytes passed these quality criteria and were used for 
further analysis.
Derived traits calculation & statistical analysis. Glycans were grouped according to their composi-
tional features. All derived traits are based on single enzymatic steps (e.g. AG for the attachment of a galactose to 
an N-acetylhexosamine). The total set of 42 calculated derived traits can be found in the Supplementary Table S2. 
Furthermore, statistical analysis was performed using IBM SPSS Statistics 20 (IBM, New York, USA). All derived 
traits were tested for normality using a Shapiro-Wilk test45. As part of the derived traits were not normally dis-
tributed, a Wilcoxon signed-rank test was used to test pairwise differences observed in the cohort46. All 42 traits 
were tested by comparing the 1st trimester with the 3rd trimester (pregnancy), the 3rd trimester with 6 WPP (short 
term recovery) and, lastly, the 3rd trimester with 26+ WPP (long term recovery). Bonferroni correction was used 
to address the multiple testing problem, by adjusting the significance threshold (significance level α < 0.0012 for 
42 tests per time point)33.
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